IN2014MN01419A - - Google Patents

Info

Publication number
IN2014MN01419A
IN2014MN01419A IN1419MUN2014A IN2014MN01419A IN 2014MN01419 A IN2014MN01419 A IN 2014MN01419A IN 1419MUN2014 A IN1419MUN2014 A IN 1419MUN2014A IN 2014MN01419 A IN2014MN01419 A IN 2014MN01419A
Authority
IN
India
Prior art keywords
molecular entities
spirostanic
general formula
steroid derivatives
epoxidising
Prior art date
Application number
Other languages
English (en)
Inventor
Pupo Laura Garcia
Figueredo Yanier Nuñez
Morales Juan Enrique Tacoronte
Reyes Yamila Verdecia
Rodriguez Estael Ochoa
Original Assignee
Ct De Investigacion Y Desarrollo De Los Medicamentos Cidem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Investigacion Y Desarrollo De Los Medicamentos Cidem filed Critical Ct De Investigacion Y Desarrollo De Los Medicamentos Cidem
Publication of IN2014MN01419A publication Critical patent/IN2014MN01419A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/005—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN1419MUN2014 2011-12-27 2012-12-27 IN2014MN01419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2011000244A CU20110244A7 (es) 2011-12-27 2011-12-27 Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
PCT/CU2012/000008 WO2013097835A1 (es) 2011-12-27 2012-12-27 Sistemas espiroesteroidales con efectos neuroactivos y anti- inflamatorios

Publications (1)

Publication Number Publication Date
IN2014MN01419A true IN2014MN01419A (es) 2015-04-03

Family

ID=47665756

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1419MUN2014 IN2014MN01419A (es) 2011-12-27 2012-12-27

Country Status (9)

Country Link
US (1) US20150140088A1 (es)
EP (1) EP2801581A1 (es)
JP (1) JP2015506929A (es)
AR (1) AR089491A1 (es)
BR (1) BR112014016127A2 (es)
CA (1) CA2861958A1 (es)
CU (1) CU20110244A7 (es)
IN (1) IN2014MN01419A (es)
WO (1) WO2013097835A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104558085B (zh) * 2014-12-16 2016-08-17 吉林农业大学 萘甲酸环戊烷并多氢菲酯b及其提取方法和药物用途
CN109053854B (zh) * 2018-09-29 2021-05-14 深圳清博汇能医药科技有限公司 基于知母菝契皂苷元结构的衍生物、药物组合物及其应用
CN110452283B (zh) * 2019-04-24 2020-09-25 西南民族大学 一种抗肿瘤季铵盐类衍生物及其制备方法及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1058988B (de) * 1957-05-03 1959-06-11 British Drug Houses Ltd Verfahren zur Herstellung von 3ª‰-Hydroxy-6-methyl-?-steroiden
US3002969A (en) * 1957-05-03 1961-10-03 British Drug Houses Ltd 3beta-hydroxy-6-methyl-delta5-steroids and method of preparation
US3105068A (en) * 1961-03-09 1963-09-24 Sato Yoshio Improved preparation of allopregnenolone and pregnadienolone from tomatidine and solasodine
DE1804331A1 (de) * 1967-10-23 1969-05-22 Erba Carlo Spa Derivate von (25R)-3ss-Amino-5alpha-22alpha-spirostan und Verfahren zu deren Herstellung
US5116829A (en) 1990-04-23 1992-05-26 Kao Corporation Steroid compounds
JPH04230696A (ja) * 1990-12-28 1992-08-19 Sanwa Shiyouyaku Kk 新規なステロイド系化合物および制癌剤
BR9306619A (pt) * 1992-06-26 1998-12-08 Pfizer Glicosídeos esteroidais para o tratamento da hipercolesterolemia
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
CA2136803A1 (en) 1993-12-22 1995-06-23 Kazumi Ogata Steroid derivatives
CU22860A1 (es) * 1995-10-12 2003-05-26 Univ La Habana Espirostanonas con funciones oxigenadas en el anillo a. como reguladores del crecimiento vegetal y su procedimiento de obtención
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
IT1311922B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0003524D0 (en) 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363984A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
CA2479249A1 (en) 2002-03-15 2003-09-25 Samaritan Pharmaceuticals, Inc. Neuroprotective spirostenol pharmaceutical compositions
BR0308788A (pt) * 2002-03-27 2005-01-11 Phytopharm Plc Processos terapêuticos e usos de sapogeninas e seus derivados
PL213697B1 (pl) * 2002-03-27 2013-04-30 Phytopharm Plc Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych
GB0523550D0 (en) 2005-11-18 2005-12-28 Hunter Fleming Ltd Therapeutic uses of steroidal compounds
JP2011027429A (ja) * 2009-07-21 2011-02-10 Kirin Holdings Co Ltd 液体クロマトグラフィーを用いたグリコアルカロイド類の精製および分析法
BR112013001422A2 (pt) * 2010-07-20 2019-09-24 Phytopharm Plc metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson

Also Published As

Publication number Publication date
CU20110244A7 (es) 2013-08-29
JP2015506929A (ja) 2015-03-05
BR112014016127A2 (pt) 2017-07-04
WO2013097835A1 (es) 2013-07-04
CA2861958A1 (en) 2013-07-04
US20150140088A1 (en) 2015-05-21
AR089491A1 (es) 2014-08-27
EP2801581A1 (en) 2014-11-12

Similar Documents

Publication Publication Date Title
BR112016009047A2 (pt) Uso de moléculas de ligação à semaforina-4d para tratar transtornos neurodegenerativos
DOP2017000213A (es) Derivados de bencimidazol como inhibidores de bromodominio
NI201200066A (es) Métodos de síntesis y purificación de compuestos heteroarilos
CL2015002391A1 (es) Derivado de tetrahidroimidazol [1,5-d] [1,4] oxazepina.
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
WO2012114204A3 (en) Methods of treating mitochondrial dysfunction
MD4666B1 (ro) Inhibitori ai Syk
MX2020001262A (es) Compuestos de platino a base de lipido y nanoparticulas.
WO2012109476A3 (en) Methods and compositions related to staufen 1 binding sites formed by duplexing alu elements
MX342310B (es) Compuestos de tiazolopirimidina.
IN2014DN05772A (es)
PE20151079A1 (es) Tratamiento para artritis reumatoide
CO2019001871A2 (es) Derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunes o inflamatorias o cánceres.
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
FR2973031B1 (fr) Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
CR20150245A (es) Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer
PH12013502530A1 (en) Glioblastoma inhibiting compounds and their use
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
IN2014MN00976A (es)
MX2013014421A (es) Procedimiento para la preparacion de una composicion que comprende complejos metalicos en una matriz organica aceitosa.
EA201491448A1 (ru) Применение 1h-индазол-3-карбоксамидных соединений в качестве ингибиторов гликогенсинтазы киназы 3-бета
EA201391173A1 (ru) Изоксазолидиновые производные
BR112016001928A2 (pt) derivados de piperidina ureia
MX358542B (es) Composición farmacéutica tópica, proceso de producción de la composición farmacéutica tópica, uso de la composición farmacéutica tópica y método de tratamiento tópico de psoriasis, dermatitis atópica o eczemas crónicos.